Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Valentina Panzeri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8930-7222; OpenAlex author ID A5034779699. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 8

  1. Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment. Co-author DOI 10.1002/pro.70444↗
  2. U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoint integrity Co-author DOI 10.1186/s13046-026-03795-3↗
  3. DDX21 Controls Cell Cycle Progression and Autophagy in Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers17040570↗
  4. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101411↗
  5. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.12847↗
  6. RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features. Co-author DOI 10.3390/cells9122561↗
  7. Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death. First author DOI 10.3892/or.2018.6233↗
  8. Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells. First author DOI 10.1038/cddis.2017.562↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Claudio Sette · 8 shared papers, 2017–2026 · strength 1.36
  2. Veronica Ruta · 5 shared papers, 2020–2026 · strength 1.07
  3. Gabriele Capurso · 5 shared papers, 2017–2024 · strength 0.55
  4. Adriana Leccese · 2 shared papers, 2024–2025 · strength 0.45
  5. Giuseppe Quero · 2 shared papers, 2024–2026 · strength 0.41
  6. Chiara Naro · 2 shared papers, 2021–2024 · strength 0.28
  7. Annalisa Pia Abbinantefina · 1 shared paper, 2026 · strength 0.28
  8. Gianni Colotti · 1 shared paper, 2026 · strength 0.28
  9. Claudio Doglioni · 2 shared papers, 2020–2024 · strength 0.26
  10. Lívia Archibugi · 2 shared papers, 2020–2024 · strength 0.26
  11. Massimo Falconi · 2 shared papers, 2020–2024 · strength 0.26
  12. Paolo Giorgio Arcidiacono · 2 shared papers, 2020–2024 · strength 0.26
  13. Juan Carlos López-Gil · 1 shared paper, 2026 · strength 0.25
  14. Ana Galván-del-Rey · 1 shared paper, 2026 · strength 0.25
  15. Carmen E. Guerra · 1 shared paper, 2026 · strength 0.25
  16. Ilaria Passacantilli · 2 shared papers, 2017–2018 · strength 0.17
  17. Gianfranco Delle Fave · 2 shared papers, 2017–2018 · strength 0.17
  18. Chantal Allgöwer · 1 shared paper, 2024 · strength 0.16
  19. Sergio Alfieri · 1 shared paper, 2024 · strength 0.16
  20. Alexander Kleger · 1 shared paper, 2024 · strength 0.16
  21. Giampaolo Tortora · 1 shared paper, 2024 · strength 0.16
  22. Carmine Carbone · 1 shared paper, 2024 · strength 0.16
  23. Luisa de Latouliere · 1 shared paper, 2021 · strength 0.12
  24. Giulia Piaggio · 1 shared paper, 2021 · strength 0.12
  25. Sabrina Gloria Giulia Testoni · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.